California State Teachers Retirement System cut its position in shares of Chimerix Inc. (NASDAQ:CMRX) by 7.4% during the second quarter, Holdings Channel reports. The fund owned 89,516 shares of the biopharmaceutical company’s stock after selling 7,157 shares during the period. California State Teachers Retirement System owned approximately 0.19% of Chimerix worth $352,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CMRX. Alps Advisors Inc. raised its position in Chimerix by 25.1% in the second quarter. Alps Advisors Inc. now owns 64,919 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 13,023 shares during the last quarter. Acadian Asset Management LLC bought a new position in Chimerix during the second quarter worth about $159,000. Opaleye Management Inc. bought a new position in Chimerix during the first quarter worth about $3,449,000. Royal Bank of Canada raised its position in Chimerix by 9,017.0% in the first quarter. Royal Bank of Canada now owns 24,160 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 23,895 shares during the last quarter. Finally, A.R.T. Advisors LLC raised its position in Chimerix by 3,008.7% in the first quarter. A.R.T. Advisors LLC now owns 866,059 shares of the biopharmaceutical company’s stock worth $4,425,000 after buying an additional 838,200 shares during the last quarter. 66.12% of the stock is currently owned by institutional investors and hedge funds.
Shares of Chimerix Inc. (NASDAQ:CMRX) traded down 3.62% during mid-day trading on Friday, hitting $4.52. The stock had a trading volume of 323,955 shares. Chimerix Inc. has a 12-month low of $3.50 and a 12-month high of $43.37. The company has a 50 day moving average price of $5.16 and a 200 day moving average price of $4.79. The firm’s market cap is $208.89 million.
Chimerix (NASDAQ:CMRX) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.12. Chimerix had a negative return on equity of 34.75% and a negative net margin of 1,356.50%. The company had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.98 million. Equities analysts forecast that Chimerix Inc. will post ($1.78) earnings per share for the current fiscal year.
A number of analysts recently weighed in on CMRX shares. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Tuesday, October 4th. Piper Jaffray Cos. set a $12.00 price target on Chimerix and gave the company a “buy” rating in a research note on Thursday, August 18th. FBR & Co decreased their price target on Chimerix from $9.00 to $8.00 and set a “mkt perform” rating on the stock in a research note on Tuesday, August 9th. Finally, JPMorgan Chase & Co. restated a “hold” rating and issued a $7.00 price target on shares of Chimerix in a research note on Tuesday, August 9th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Chimerix currently has a consensus rating of “Hold” and a consensus target price of $12.38.
In other news, Director John M. Leonard sold 5,000 shares of Chimerix stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $5.03, for a total transaction of $25,150.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider M Michelle Berrey purchased 22,417 shares of the stock in a transaction dated Monday, August 29th. The shares were purchased at an average price of $4.47 per share, for a total transaction of $100,203.99. Following the completion of the transaction, the insider now owns 281,238 shares in the company, valued at approximately $1,257,133.86. The disclosure for this purchase can be found here. Insiders own 10.50% of the company’s stock.
Chimerix Company Profile
Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.
Want to see what other hedge funds are holding CMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chimerix Inc. (NASDAQ:CMRX).
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.